Rociletinib
- Generic Name
- Rociletinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H28F3N7O3
- CAS Number
- 1374640-70-6
- Unique Ingredient Identifier
- 72AH61702G
- Background
Rociletinib has been used in trials studying the treatment and prevention of Nonsmall Cell Lung Cancer, Non-small Cell Lung Cancer, and Locally Advanced or Metastatic Non-small Cell Lung Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2016-05-17
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT02705339
A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02630186
- Locations
- 🇺🇸
University of California at Los Angeles, Santa Monica, California, United States
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02580708
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Tennessee Oncology, PLLC - The Sarah Cannon Research Institute, Nashville, Tennessee, United States
Rociletinib (CO-1686) USA Expanded Access Program
- Conditions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Clovis Oncology, Inc.
- Registration Number
- NCT02547675
- Locations
- 🇺🇸
Billings Clinic, Billings, Montana, United States
🇺🇸Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Sutter Cancer Institute, Sacramento, California, United States
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 149
- Registration Number
- NCT02322281
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Saint Joseph Heritage Healthcare, Fullerton, California, United States
🇺🇸University of California at Los Angeles, Santa Monica, California, United States
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer
- First Posted Date
- 2014-05-28
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 318
- Registration Number
- NCT02147990
- Locations
- 🇺🇸
UCLA Medical Center, Alhambra, California, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Saint Jude Heritage Healthcare, Fullerton, California, United States
Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Interventions
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Clovis Oncology, Inc.
- Target Recruit Count
- 612
- Registration Number
- NCT01526928
- Locations
- 🇺🇸
University of California, Irvine, Orange, California, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸UCLA Health System, Santa Monica, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.